Meeder Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Meeder Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3	Closed	–	–	2472
2021 Q2	$0	Hold	3	–	–	﹤0.01%	2504
2021 Q1	$0	Hold	3	–	–	﹤0.01%	2351
2020 Q4	$1K	Sell	3 -6	-67%	-$992	﹤0.01%	1591
2020 Q3	$1K	Hold	9	–	–	﹤0.01%	1923
2020 Q2	$1K	Hold	9	–	–	﹤0.01%	1855
2020 Q1	$1K	Hold	9	–	–	﹤0.01%	2161
2019 Q4	$1K	Buy	+9	New	+$1K	﹤0.01%	2111

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Meeder Asset Management's ASND Position: Q3 2021 in Review

Meeder Asset Management sold out of Ascendis Pharma A/S (ASND) in Q3 2021, closing a stake of 3 shares.

Meeder Asset Management first reported a position in ASND in Q4 2019 and held it in 7 quarters. The position peaked at $1K in Q4 2020. 166 funds tracked by Wall St. Rank hold ASND as of Q3 2021.

Meeder Asset Management reported no remaining Ascendis Pharma A/S position as of Q3 2021 after selling out during the quarter.
Meeder Asset Management sold 3 Ascendis Pharma A/S shares in Q3 2021.
Meeder Asset Management first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 7 quarters.
Meeder Asset Management's Ascendis Pharma A/S position peaked at $1K in Q4 2020.
166 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.